https://www.fool.com.au/2018/06/06/5-under-the-radar-shares-for-savvy-generation-y-investors/
Clinuvel Pharmaceuticals Limited (ASX: CUV)
No well-diversified Gen Y share portfolio would be complete without a biotech company, and while most will consider CSL Limited (ASX: CSL) to be on the expensive side, emerging players like Clinuvel Pharmaceuticals could be a consideration.
This $570 million market cap company appears to be kicking goals of late, with its focus on drugs for severe skin disorders gaining traction as Clinuvel manages to report positive cash flow of $230,000 for the quarter ending March 31, 2018, despite continued research and development efforts for its novel drug SCENESSE.
Clinuvel looks to operate in a financially disciplined manner and labels itself a “pioneer” in the photomedicine space.
One to watch for sure.
Motley fools
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $741.1M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |
